Intervention not reported
Antibiotic versus heparin only lock/flush solution: adverse events · adults and children diagnosed with an oncologic disease with a newly‐inserted long‐term CVC who were at risk of neutropenia due to…
1 finding from 1 review
acceptability ‐ drop‐outs due to adverse events: post‐intervention · adults with long‐term physical conditions (18 years or older)
It is very uncertain whether pharmacological interventions changes acceptability ‐ drop‐outs due to adverse events: post‐intervention compared with placebo (very low certainty).
1 finding from 1 review
Adverse events; · people with dementia
1 finding from 1 review
Serious adverse events related to the use of physical restraints ‐ not measured · older people in all long‐term care settings
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (pain) · adults requiring radial artery catheterisation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse outcome: unintended adverse events attributable to the intervention Multimodal/complex intervention, ATCS Plus, IVR versus various controls · participants at risk of developing long‐term conditions
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ( · adult patients with an implantable cardioverter defibrillator
It is very uncertain whether exercise changes serious adverse events ( compared with no exercise at longest available follow‐up (very low certainty).
1 finding from 1 review
Adverse events: ED visits · people with pressure ulcers residing in long‐term‐care facilities
1 finding from 1 review
All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Phentermine/topiramate may leads to higher all adverse events compared with placebo (low certainty).
1 finding from 1 review
All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion probably leads to higher all adverse events compared with placebo (moderate certainty).
1 finding from 1 review
All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
It is very uncertain whether orlistat changes all adverse events compared with placebo (very low certainty).
1 finding from 1 review
All adverse events · children with previous UTI and most do not have a renal tract abnormality such as VUR
Antibiotic treatment showed no clear difference in all adverse events compared with placebo or no treatment (low certainty).
1 finding from 1 review
Adverse events Not measured · patients with trigger finger
The review found no eligible studies for this question.
2 findings from 1 review
Adverse events ‐ short term · people suspected to have meningococcal disease (adults and children)
1 finding from 1 review
Adverse events: Not reported · Adolescents with psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (all) · adults with asthma well controlled on LABA and ICS
Stopping LABA showed no clear difference in adverse events (all) compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Adverse events(during · children or adults with Types I or II HAE
Berotralstat showed no clear difference in adverse events(during compared with placebo or active control (moderate certainty).
1 finding from 1 review
Adverse events(during · children or adults with Types I or II HAE
Plasma‐derived C1 esterase inhibitor showed no clear difference in adverse events(during compared with placebo or active control (low certainty).
1 finding from 1 review
Adverse events(during · children or adults with Types I or II HAE
Recombinant human C1 esterase inhibitor showed no clear difference in adverse events(during compared with placebo or active control (low certainty).
1 finding from 1 review
Adverse events(during · children or adults with Types I or II HAE
Lanadelumab showed no clear difference in adverse events(during compared with placebo or active control (low certainty).
1 finding from 1 review